Jupiter Neurosciences will present its clinical and commercial updates at the Emerging Growth Conference on April 2, 2026.
Quiver AI Summary
Jupiter Neurosciences, Inc. announced that it will present its clinical and commercial advancements at the Emerging Growth Conference 91 on April 2, 2026, at 10:15 AM ET. The Company, which is focused on developing JOTROL™, a patented resveratrol-based platform, aims to address neuroinflammation and promote healthy aging through its therapeutic pipeline targeting CNS disorders and a consumer longevity line called Nugevia™. The conference provides a platform for public companies to engage with investors, and participants can access the live presentation through a web link, with an archived version available afterward. Jupiter's product line includes three formulations aimed at mitochondrial support, cognitive health, and skin vitality, leveraging their proprietary micellar delivery technology. The press release also includes forward-looking statements subject to risks affecting their business outcomes.
Potential Positives
- Jupiter Neurosciences has been invited to present at the Emerging Growth Conference, showcasing its clinical and commercial progress, which can enhance visibility and credibility among investors.
- The presentation will allow Jupiter to engage with a wide audience of individual and institutional investors, potentially increasing interest in its therapeutic products and pipeline.
- Jupiter's participation in this conference highlights its commitment to increasing investor awareness and transparency regarding its innovative solutions in neuroinflammation and healthy aging.
- The company's JOTROL™ platform, which has shown improved bioavailability in clinical studies, positions it favorably in the competitive landscape of CNS disorders and consumer longevity markets.
Potential Negatives
- Jupiter Neurosciences is still in the clinical stage, indicating that its products, specifically JOTROL™ and its therapeutics, have not yet proven successful or gained regulatory approval.
- The company faces significant risks and uncertainties related to clinical trial outcomes and regulatory developments, which could adversely impact its business and market acceptance of its products.
- There is potential concern over capital market conditions and Nasdaq listing requirements, which may affect the company's ability to secure financing and maintain its public listing status.
FAQ
What is Jupiter Neurosciences, Inc.?
Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on addressing neuroinflammation and promoting healthy aging.
What is JOTROL™?
JOTROL™ is a patented resveratrol-based platform developed by Jupiter that improves bioavailability for therapeutic applications.
When is Jupiter's presentation at the Emerging Growth Conference?
Jupiter will present at the Emerging Growth Conference on April 2, 2026, at 10:15 AM ET.
How can I attend Jupiter's conference presentation?
You can attend the presentation live by visiting the web link provided in the press release.
What products are offered under the Nugevia™ brand?
Nugevia™ includes formulations for mitochondrial support, cognitive health, and skin vitality, all utilizing JOTROL™ technology.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$JUNS Hedge Fund Activity
We have seen 10 institutional investors add shares of $JUNS stock to their portfolio, and 3 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VESTOR CAPITAL, LLC removed 970,314 shares (-99.9%) from their portfolio in Q4 2025, for an estimated $989,720
- YORKVILLE ADVISORS GLOBAL, LP added 131,909 shares (+inf%) to their portfolio in Q4 2025, for an estimated $134,547
- VANGUARD GROUP INC added 33,100 shares (+15.3%) to their portfolio in Q4 2025, for an estimated $33,762
- ALLEN CAPITAL GROUP, LLC added 30,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $30,600
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 29,274 shares (+inf%) to their portfolio in Q4 2025, for an estimated $29,859
- GEODE CAPITAL MANAGEMENT, LLC added 28,826 shares (+27.8%) to their portfolio in Q4 2025, for an estimated $29,402
- CITIGROUP INC removed 12,418 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $12,666
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
JUPITER, FL, March 31, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL ™ , a patented resveratrol-based platform, is pleased to announce that it has been invited to present its clinical and commercial progress at the Emerging Growth Conference 91 on April 2, 2026, at 10:15 AM ET. Jupiter invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference at: https://goto.webcasts.com/starthere.jsp?ei=1748971&tp_key=add80b0ab6&sti=juns
If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event on EmergingGrowth.com and on the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference .
About the Emerging Growth Conference
The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner. The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts. All sessions will be conducted through video webcasts and will take place in the Eastern time zone.
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia ™ product line. Both efforts are powered by JOTROL ™ , Jupiter’s proprietary, enhanced resveratrol formulation that has demonstrated improved bioavailability in clinical studies. The Company’s prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson’s disease, including indications such as Alzheimer’s Disease, Mucopolysaccharidoses Type I, Friedreich’s Ataxia, and MELAS.
Nugevia is Jupiter’s consumer longevity product line, powered by the same proprietary JOTROL ™ micellar delivery technology that underpins the Company’s clinical pipeline. The product line currently includes three formulations: PWR (mitochondrial support), MND (cognitive health), and GLO (skin vitality). Products are available direct-to-consumer at www.nugevia.com , and the Company is now expanding into practitioner-led channels where the formulations’ clinical-grade bioavailability profile can be a differentiator.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those described in such statements. Factors that could cause actual results to differ materially include clinical trial outcomes, regulatory developments, market acceptance of Nugevia, the ability to successfully develop and execute distribution partnerships, capital market conditions, Nasdaq listing requirements, and other risks described in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements except as required by law.
Contact:
Jupiter Neurosciences, Inc.
1001 North US Highway 1, Suite 504
Jupiter, FL 33477
Email:
[email protected]
